Clinical Trial Update: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating AK104 plus lenvatinib with transarterial chemoembolization versus TACE alone in incurable/non-metastatic hepatocellular carcinoma; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Akeso | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: RECRUITING